Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AccurKardia logo — ECG-led Diagnostics

AccurKardia

ECG-led Diagnostics

Founded 2019 United States New York, United States 14 employees Non Equity Assistance Total: $4.27M AI, Analytics +2

General Information

Company Name AccurKardia
Founded Year 2019
Location United States New York, United States
Founders / Decision Makers
Team member
Employees 14
Industries AI, Analytics, Health Care +1
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with AccurKardia. To contact AccurKardia, visit accurkardia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AccurKardia compare?

A PDF of AccurKardia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AccurKardia soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AccurKardia

AccurKardia is a United States-based analytics startup founded in 2019. The company specializes in ECG-led diagnostics and aims to revolutionize the diagnostic coverage and disease management in cardiology and other related fields. The flagship product, AccurECG, is an FDA cleared (Class II SaMD) software intended to automate ECG interpretation and detect up to 13 arrhythmias. This innovative product is designed to facilitate the analysis of ECGs recorded from holters, event recorders, and cardiac telemetry devices, and has potential applications beyond cardiology. Moreover, the company has gained recognition by being accepted into the MedTech Innovator 2024 Cohort and the Heart and Brain Health Accelerator track in collaboration with the American Heart Association’s Center for Health Technology and Innovation. The latest investment received by AccurKardia was a Non Equity Assistance investment on 29 May 2024, with the investment coming from MedTech Innovator. This undoubtedly signals the investor's confidence in the potential of the company and its products. With its cutting-edge technology and substantial industry recognition, AccurKardia is well-positioned for growth and may have a significant impact on the future of diagnostics and disease management, both in cardiology and across other medical fields.

Business keywords: ECG analysis, cardiac healthcare, healthtech, medtech, digital health, remote patient monitoring, diagnostics

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
MedTech Innovator
MedTech Innovator
29 May 2024
Seed Round $2.70M 2
Mayo Clinic Platform
Mayo Clinic Platform, Popular Impact Fund
20 Jun 2023
Pre Seed Round $500.00K -
13 Jul 2021
Pre Seed Round $340.00K -
01 Apr 2021
Pre Seed Round $570.00K -
31 Jan 2020
Pre Seed Round $160.00K 1
Root NYC
Root NYC
01 Apr 2019

AccurKardia Alternatives & Competitors

View All Alternatives
AccurKardia vs
Cardiolyse
Cardiolyse Finland

Medical-grade Heart Health AI

11 employees
Analytics, Digital Health
AccurKardia vs
山东优加利信息科技有限公司
山东优加利信息科技有限公司 China

优加利企业是一家心脏远程实时监护整体解决方案供应商，主打产品为心脏远程实时监护技术（iHolter心安宝）...

Series A
3 employees
AI, Health Care
AccurKardia vs
Idoven
Idoven Spain

Re-defining the way cardiovascular diseases are detected and treated with Artificial Intelligence (A...

Venture round
63 employees
AI, Health Care
Compare AccurKardia vs Idoven
Also compare with: AccurKardia vs Cardiologs Cardiologs View all alternatives

FAQ About AccurKardia

ECG-led Diagnostics
AccurKardia was founded in 2019.
AccurKardia is headquartered in New York, United States.
AccurKardia operates in AI, Analytics, Health Care and IoT. Its work centres on ECG analysis, cardiac healthcare, healthtech and medtech.
AccurKardia has approximately 14 employees.
AccurKardia has completed 6 funding rounds, raising a total of $4.27M. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to AccurKardia include Cardiolyse, 山东优加利信息科技有限公司, Idoven, Cardiomo, Implicity. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AccurKardia and Cardiolyse are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AccurKardia, https://bouncewatch.com/company/accurkardia, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout